Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study

Ning Li, Zhi Li, Qiang Fu, Bin Zhang, Jian Zhang, Xiangbin Wan, Chao-min Lu, Jin-Bang Wang, Wenying Deng, Yi-Jie Ma, Liangyu Bie, Mengyu Wang, Jing Li, Qingxin Xia, Wei Chen, Suxia LuoInternational Journal of Surgery 2024 · DOI

Abstract

The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population.
BibTeX
@article{li2024efficacy,
  author = {Ning Li and Zhi Li and Qiang Fu and Bin Zhang and Jian Zhang and Xiangbin Wan and Chao-min Lu and Jin-Bang Wang and Wenying Deng and Yi-Jie Ma and Liangyu Bie and Mengyu Wang and Jing Li and Qingxin Xia and Wei Chen and Suxia Luo},
  title = {{Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study}},
  journal = {International Journal of Surgery},
  year = {2024},
  doi = {10.1097/js9.0000000000001119},
}

Loading related content...

Figure